{"abstract":"In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled \"Expansion of Buprenorphine Treatment via Telemedicine Encounter\" and \"Continuity of Care via Telemedicine for Veterans Affairs Patients.\" These final rules were originally scheduled to become final on February 18, 2025. In accordance with the Presidential Memorandum of January 20, 2025, titled \"Regulatory Freeze Pending Review,\" the Drug Enforcement Administration and the Department of Health and Human Services delayed the effective dates of these two final rules to March 21, 2025, by issuing a final rule; delay of effective dates and request for comments in the February 19, 2025, issue of the Federal Register. The Drug Enforcement Administration received 32 comments in response to the request for public comments regarding the delayed effective date. Considering these comments, the Department of Justice wishes to further postpone the effective dates for the purpose of further reviewing any questions of fact, law, and policy that the rules may raise. Therefore, the Drug Enforcement Administration and the Department of Health and Human Services will delay the effective date of the two final rules titled \"Expansion of Buprenorphine Treatment via Telemedicine Encounter\" and \"Continuity of Care via Telemedicine for Veterans Affairs Patients\" to December 31, 2025.","action":"Final rule.","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2025/03/24/2025-05007.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"1306","title":21},{"chapter":null,"citation_url":null,"part":"12","title":42}],"citation":"90 FR 13410","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"As of March 20, 2025, the effective dates of the final rules amending 21 CFR part 1306 and 42 CFR part 12 published in the Federal Register on January 17, 2025, at 90 FR 6504 and 90 FR 6523, respectively, are effective December 31, 2025.","disposition_notes":null,"docket_ids":["Docket No. DEA-948","DEA-407VA"],"dockets":[{"supporting_documents":[],"agency_name":"DEA","documents":[{"comment_count":0,"comment_start_date":"2025-03-24","updated_at":"2025-06-02T16:55:54.829-04:00","comment_url":"https://www.regulations.gov/commenton/DEA-2023-0028-2951","allow_late_comments":false,"id":"DEA-2023-0028-2951","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"DEA-2023-0028","title":"Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948)"},{"supporting_documents":[],"agency_name":"HHS","documents":[{"comment_count":0,"comment_start_date":"2025-03-24","updated_at":"2026-07-27T09:57:37.107-04:00","comment_url":"https://www.regulations.gov/commenton/HHS-OS-2025-0001-0014","allow_late_comments":false,"id":"HHS-OS-2025-0001-0014","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"HHS-OS-2025-0001","title":"HHS 2025 Publications"}],"document_number":"2025-05007","effective_on":"2025-12-31","end_page":13412,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2025/03/24/2025-05007.xml","html_url":"https://www.federalregister.gov/documents/2025/03/24/2025-05007/expansion-of-buprenorphine-treatment-via-telemedicine-encounter-and-continuity-of-care-via","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2025-05007?publication_date=2025-03-24","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2025-03-24/2025-05007/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":7666,"last_updated":"2026-09-29 02:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-03-24/pdf/2025-05007.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-05007.pdf?1742501707","publication_date":"2025-03-24","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2025/03/24/2025-05007.txt","regulation_id_number_info":{"1117-AB40":{"issue":"202504","html_url":"https://www.federalregister.gov/regulations/1117-AB40/special-registrations-for-telemedicine-and-limited-state-telemedicine-registrations","title":"Special Registrations for Telemedicine and Limited State Telemedicine Registrations","xml_url":"http://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202504&RIN=1117-AB40&operation=OPERATION_EXPORT_XML","priority_category":"Other Significant"},"1117-AB78":{"issue":"202504","html_url":"https://www.federalregister.gov/regulations/1117-AB78/expansion-of-induction-of-buprenorphine-via-telemedicine-encounter-","title":"Expansion of Induction of Buprenorphine via Telemedicine Encounter\n","xml_url":"http://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202504&RIN=1117-AB78&operation=OPERATION_EXPORT_XML","priority_category":"Other Significant"},"1117-AB88":null},"regulation_id_numbers":["1117-AB40","1117-AB78","1117-AB88"],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"HHS","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=HHS-OS-2025-0001","supporting_documents_count":0,"docket_id":"HHS-OS-2025-0001","document_id":"HHS-OS-2025-0001-0014","regulation_id_number":null,"title":"HHS 2025 Publications","checked_regulationsdotgov_at":"2026-07-28T16:55:04Z"},"regulations_dot_gov_url":null,"significant":true,"signing_date":null,"start_page":13410,"subtype":null,"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients","toc_doc":"Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients","toc_subject":null,"topics":[],"type":"Rule","volume":90}